Recently, immunotherapy, such as immune-checkpoint blockade programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1), has further improved the prognosis of patients with CRC, especially those with late-stage cancer [3, 4]. The gene discussed is CD274; the disease is colorectal carcinoma.